GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » EPS without NRI

Entheon Biomedical (XCNQ:ENBI) EPS without NRI : C$-0.05 (TTM As of Feb. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical EPS without NRI?

Entheon Biomedical's earnings per share without non-recurring items for the three months ended in Feb. 2024 was C$-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.05.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 40.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Entheon Biomedical's EPS without NRI or its related term are showing as below:

XCNQ:ENBI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -263.4   Med: -31.15   Max: 40.3
Current: 40.3

During the past 7 years, Entheon Biomedical's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 40.30% per year. The lowest was -263.40% per year. And the median was -31.15% per year.

XCNQ:ENBI's 3-Year EPS without NRI Growth Rate is ranked better than
86.3% of 1299 companies
in the Biotechnology industry
Industry Median: 5.2 vs XCNQ:ENBI: 40.30

Entheon Biomedical's EPS (Diluted) for the three months ended in Feb. 2024 was C$-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.04.

Entheon Biomedical's EPS (Basic) for the three months ended in Feb. 2024 was C$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.04.


Entheon Biomedical EPS without NRI Historical Data

The historical data trend for Entheon Biomedical's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical EPS without NRI Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
EPS without NRI
Get a 7-Day Free Trial -0.34 -0.24 -1.54 -0.34 -0.05

Entheon Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.02 -0.02 -0.01

Competitive Comparison of Entheon Biomedical's EPS without NRI

For the Biotechnology subindustry, Entheon Biomedical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's PE Ratio without NRI falls into.



Entheon Biomedical EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entheon Biomedical  (XCNQ:ENBI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Entheon Biomedical EPS without NRI Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.
Executives
Brian Jahns Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines